|
시장보고서
상품코드
2077291
PARP 억제제 바이오마커 시장 : 제품 및 서비스별, 용도별, 지역별PARP Inhibitor Biomarkers Market, by Product & Services, by Application and by Region |
||||||
가격
※ 부가세 별도
한글목차
영문목차
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.
PARP 억제제 바이오마커 시장은 2026년에 17억 7,000만 달러 규모에 달할 것으로 추정되며, 2033년까지 84억 8,760만 달러에 달할 것으로 예상됩니다. 2026년부터 2033년까지 CAGR 25.1%로 성장할 것으로 전망됩니다.
| 보고서 범위 | 보고서 상세 | ||
|---|---|---|---|
| 기준 연도: | 2025년 | 2026년 시장 규모: | 17억 7,000만 달러 |
| 과거 데이터 기간: | 2020-2024년 | 예측 기간: | 2026-2033년 |
| 2026년부터 2033년까지 예측 기간의 CAGR: | 25.10% | 2033년 시장 규모 예측: | 84억 8,760만 달러 |
인체 세포의 유전체 무결성은 인체의 메커니즘이 모든 생리적 및 면역학적 기능을 최적으로 발휘하는 데 기여합니다. 유전체 불안정성으로 인해 유전체의 완전성이 훼손되면, 인체에 생명을 위협하는 변화가 일어나며, 면역 기능에 중대한 영향을 미칩니다. 인간 세포의 유전체 무결성이 최고 수준을 초과하면 암의 발생과 진행을 유발합니다. 암세포는 폴리(ADP-리보스) 폴리머라제(PARP) 등의 단백질의 도움을 받아 생존하고 증식합니다. 폴리(ADP-리보스) 폴리머라제(PARP)는 암세포가 스스로를 복구하도록 돕는 단백질의 일종입니다. 이 단백질은 유전체의 무결성 유지, DNA 복구, 프로그램된 세포 사멸과 같은 필수적인 세포 기능을 담당하고 있습니다. DNA 복구란, 유전체의 완전성과 안정성을 훼손하지 않으면서 DNA 분자의 손상을 파악하고 조절하기 위해 인간 세포가 수행하는 일련의 과정을 말합니다. 폴리(ADP-리보스) 폴리메라제(PARP) 억제제는 DNA 복구 과정에 관여하는 효소의 작용을 억제함으로써 암세포의 증식을 억제하는 약물 요법의 일종입니다.
시장 역학
- 주요 시장 참여자들은 새로운 PARP 억제제 바이오마커 출시 등 유기적 성장 전략의 도입에 주력하고 있으며, 이는 전 세계 PARP 억제제 바이오마커 시장의 성장에 기여하고 있습니다. 예를 들어, 2020년 3월, 의료 기술 기업인 BD(벡톤 디킨슨 앤 컴퍼니)와 미국에 본사를 둔 비상장 임상 진단 기업인 BioMedomics는 혈액 내 항체를 검출하여 PARP 바이오마커 검사에 대한 현재 또는 과거의 노출 여부를 확인할 수 있는 새로운 현장 진단 검사를, 단 15분 만에 실시할 수 있다고 발표했습니다.
본 조사의 주요 특징:
- 본 보고서는 전 세계 PARP 억제제 바이오마커 시장에 대한 상세한 분석을 수행하며, 2025년을 기준 연도로 하여 2026년부터 2033년까지의 예측 기간 동안의 시장 규모 및 연평균 성장률(CAGR)을 제시하고 있습니다. 또한, 다양한 부문에서 잠재적인 수익 기회를 파악하고, 이 시장에서 매력적인 투자 제안 매트릭스에 대해 설명하고 있습니다.
- 또한, 본 조사에서는 시장의 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 그리고 주요 기업들이 채택하는 경쟁 전략에 관한 중요한 인사이트도 제공하고 있습니다.
- 본 보고서에서는 다음의 매개변수(기업 개요, 제품 포트폴리오, 주요 하이라이트, 재무 실적, 전략)를 바탕으로 전 세계 PARP 억제제 바이오마커 시장의 주요 업체들을 분석하고 있습니다.
- 전 세계 PARP 억제제 바이오마커 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진입 기업, 금융 애널리스트 등 이 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 전 세계 PARP 억제제 바이오마커 분석에 활용되는 다양한 전략 매트릭스를 활용함으로써 의사결정을 원활하게 진행할 수 있을 것입니다.
목차
제1장 조사 목적과 가정
제2장 시장 전망
제3장 시장 역학·규제·동향 분석
제4장 세계의 PARP 억제제 바이오마커 시장
제5장 세계의 PARP 억제제 바이오마커 시장 : 제품 유형 및 서비스별, 2021-2033년
제6장 세계의 PARP 억제제 바이오마커 시장 : 용도별, 2021-2033년
제7장 세계의 PARP 억제제 바이오마커 시장 : 지역별, 2021-2033년
제8장 경쟁 구도
제9장 섹션
KSM 26.07.08Parp Inhibitor Biomarkers Market is estimated to be valued at USD 1,770.0 Mn in 2026 and is expected to reach USD 8,487.6 Mn by 2033, growing at a compound annual growth rate (CAGR) of 25.1% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 1,770.0 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 25.10% | 2033 Value Projection: | USD 8,487.6 Mn |
Genomic integrity of the human cells helps the human mechanism to perform all its physiological and immunological functions optimally. When genomic integrity is affected due to genomic instability some life-threatening changes occur in the human body affecting immunological functions significantly. When the genomic integrity of a human cell reaches beyond its peak level it causes cancer initiation and progression. The cancer cells survive and multiply with the help of proteins such as Poly(ADP-ribose) polymerase (PARP). Poly(ADP-ribose) polymerase (PARP) is a type of protein that aids cancer cells to repair themselves. It is responsible for essential cellular functions such as maintaining genomic integrity, DNA repair, and programmed cell death. DNA repair is a set of processes adopted by human cells to identify and regulate damage to the DNA molecules while keeping the genome integrity and genome stability intact. Poly(ADP-ribose) polymerase (PARP) inhibitor is a type of drug therapy that works by preventing enzymes involved in DNA repair processes thereby limiting the growth of cancer cells.
Market Dynamics
- The key market players are focusing on adoption of growth organic strategies such launching of new PARP inhibitor biomarkers, which is attributed to the growth of global PARP Inhibitor Biomarkers market. For instance, in March 2020, BD (Becton, Dickinson and Company) is a medical technology company, and BioMedomics, a privately held, U.S.-based clinical diagnostics company, announced the release of a new point-of-care test that can detect antibodies in blood to confirm current or past exposure to PARP biomarker test in as little as 15 minutes.
Key features of the study:
- This report provides an in-depth analysis of the global PARP Inhibitor Biomarkers market and provides market size (US$ Million) and compound annual growth rate (CAGR) for the forecast period 2026-2033, considering 2025 as the base year It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global PARP Inhibitor Biomarkers market based on the following parameters-Company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include include Myriad Genetics, Inc., F. Hoffmann-La Roche AG, Invitae Corporation, NeoGenomics Laboratories, Inc., and BPS Bioscience, Inc. Antibodies Inc., Networks LLC, Beckman Coulter, Inc., Euro Diagnostica AB, F. Hoffmann-La Roche Ltd., Qiagen NV, Siemens Healthcare GmbH, Bio Rad Laboratories Inc., Exagen Inc.,Genway Biotech, Inc., Microdrop LLC (imaware), Svar Life Science AB and Thermo Fisher Scientific Inc.
- Global PARP Inhibitor Biomarkers market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global PARP Inhibitor Biomarkers
Detailed Segmentation:
- Global PARP Inhibitor Biomarkers Market, By Product Type and Services (Revenue, USD Mn, 2021 - 2033)
- Product Type
- Kits
- Assays
- Services
- BRCA 1 & 2 Testing
- HRD Testing
- HRR Testing
- Others
- Global PARP Inhibitor Biomarkers Market, By Application (Revenue, USD Mn, 2021 - 2033)
- Breast Cancer
- Ovarian Cancer
- Others
- Global PARP Inhibitor Biomarkers, By Region (Revenue, USD Mn, 2021 - 2033)
- North America
- By Country:
- U.S.
- Canada
- By Country:
- Latin America
- By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- By Country:
- Europe
- By Country:
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- By Country:
- Asia Pacific
- By Country:
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- By Country:
- Middle East
- By Country:
- GCC
- Israel
- Rest of Middle East
- By Country:
- Africa
- By Country:
- South Africa
- Central Africa
- North Africa
- By Country:
- Company Profiles
- Myriad Genetics, Inc.
- F. Hoffmann-La Roche AG
- Invitae Corporation
- NeoGenomics Laboratories, Inc.
- BPS Bioscience, Inc.
- Antibodies Inc.
- Networks LLC
- Beckman Coulter, Inc.
- Euro Diagnostica AB
- F. Hoffmann-La Roche Ltd.
- Qiagen NV
- Siemens Healthcare GmbH
- Bio Rad Laboratories Inc.
- Exagen Inc.
- Genway Biotech, Inc.
- Microdrop LLC (imaware)
- Svar Life Science AB
- Thermo Fisher Scientific Inc.
Table of Contents
1. Research Objective and Assumption
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Product Type and Services
- Market Snippet, By Application
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Recent Product Launches
- Epidemiology
- Merger, Acquisition, and Collaborations
- Regulatory Scenario
- Key Developments
- PEST Analysis
4. Global PARP inhibitor biomarkers Market
- Economic Impact
- Impact on Supply and Demand
5. Global PARP inhibitor biomarkers Market, By Product Type and Services, 2021 €" 2033 (US$ Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022€"2033
- Segment Trends
- Product Type
- Tests
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 €" 2033, (US$ Mn)
- Segment Trends
- Kits
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 €" 2033, (US$ Mn)
- Segment Trends
- Tests
- Services
- BRCA 1 & 2 Testing
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 €" 2033, (US$ Mn)
- HRD Testing
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 €" 2033, (US$ Mn)
- HRR Testing
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 €" 2033, (US$ Mn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 €" 2033, (US$ Mn)
- BRCA 1 & 2 Testing
6. Global PARP inhibitor biomarkers Market, By Application, 2021 €" 2033 (US$ Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022€"2033
- Segment Trends
- Breast Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 €" 2033, (US$ Mn)
- Ovarian Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 €" 2033, (US$ Mn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 €" 2033, (US$ Mn)
7. Global PARP inhibitor biomarkers Market, By Regions, 2021 €" 2033 (US$ Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022€"2033
- Segment Trends
- North America
- Introduction
- Market Size and Forecast, By Product Type and Services, and Y-o-Y Growth 2021 €" 2033, (US$ Mn)
- Market Size and Forecast, By Application , and Y-o-Y Growth 2021 €" 2033, (US$ Mn)
- Market Size and Forecast, By Country, and Y-o-Y Growth 2021 €" 2033, (US$ Mn)
- U.S.
- Canada
- Europe
- Introduction
- Market Size and Forecast, By Product Type and Services, and Y-o-Y Growth 2021 €" 2033, (US$ Mn)
- Market Size and Forecast, By Application , and Y-o-Y Growth 2021 €" 2033, (US$ Mn)
- Market Size and Forecast, By Country, and Y-o-Y Growth 2021 €" 2033, (US$ Mn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Product Type and Services, and Y-o-Y Growth 2021 €" 2033, (US$ Mn)
- Market Size and Forecast, By Application , and Y-o-Y Growth 2021 €" 2033, (US$ Mn)
- Market Size and Forecast, By Country, and Y-o-Y Growth 2021 €" 2033, (US$ Mn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Introduction
- Market Size and Forecast, By Product Type and Services, and Y-o-Y Growth 2021 €" 2033, (US$ Mn)
- Market Size and Forecast, By Application , and Y-o-Y Growth 2021 €" 2033, (US$ Mn)
- Market Size and Forecast, By Country, and Y-o-Y Growth 2021 €" 2033, (US$ Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Middle East
- Introduction
- Market Size and Forecast, By Product Type and Services, and Y-o-Y Growth 2021 €" 2033, (US$ Mn)
- Market Size and Forecast, By Application , and Y-o-Y Growth 2021 €" 2033, (US$ Mn)
- Market Size and Forecast, By Country, and Y-o-Y Growth 2021 €" 2033, (US$ Mn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Product Type and Services, and Y-o-Y Growth 2021 €" 2033, (US$ Mn)
- Market Size and Forecast, By Application , and Y-o-Y Growth 2021 €" 2033, (US$ Mn)
- Market Size and Forecast, By Country, and Y-o-Y Growth 2021 €" 2033, (US$ Mn)
- North Africa
- Central Africa
- South Africa
8. Competitive Landscape
- Company Profiles
- Abbott Diagnostics (Abbott Laboratories) *
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Myriad Genetics, Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- F. Hoffmann-La Roche AG
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Invitae Corporation
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- NeoGenomics Laboratories, Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- BPS Bioscience
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Antibodies Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Networks LLC
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Beckman Coulter, Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Euro Diagnostica AB, F.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Hoffmann-La Roche Ltd.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Qiagen NV
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Siemens Healthcare GmbH
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Augurex Life Sciences Corp.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Thermo Fisher Scientific Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Bio Rad Laboratories Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Exagen Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Genway Biotech, Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Microdrop LLC (imaware)
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Svar Life Science AB
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Abbott Diagnostics (Abbott Laboratories) *
9. Section
- References
- Research Methodology
- About us and Sales Contact
